Chardan Capital Analysts Cut Earnings Estimates for Prothena

Prothena Co. plc (NASDAQ:PRTA - Free Report) - Research analysts at Chardan Capital dropped their FY2025 earnings per share (EPS) estimates for shares of Prothena in a report issued on Tuesday, May 27th. Chardan Capital analyst R. Li now expects that the biotechnology company will earn ($3.80) per share for the year, down from their previous forecast of ($2.95). Chardan Capital currently has a "Buy" rating and a $18.00 target price on the stock. The consensus estimate for Prothena's current full-year earnings is ($4.04) per share. Chardan Capital also issued estimates for Prothena's FY2026 earnings at ($3.55) EPS.

A number of other brokerages have also recently commented on PRTA. JMP Securities dropped their price objective on shares of Prothena from $78.00 to $29.00 and set a "market outperform" rating for the company in a research note on Tuesday, May 27th. Piper Sandler dropped their price target on Prothena from $110.00 to $81.00 and set an "overweight" rating for the company in a research report on Tuesday, May 27th. HC Wainwright dropped their price target on Prothena from $30.00 to $14.00 and set a "buy" rating for the company in a research report on Tuesday, May 27th. Cantor Fitzgerald lowered Prothena from an "overweight" rating to a "neutral" rating in a research report on Tuesday, May 27th. Finally, Jefferies Financial Group cut Prothena from a "buy" rating to a "hold" rating and set a $6.00 target price for the company. in a report on Tuesday, May 27th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Prothena presently has an average rating of "Hold" and a consensus price target of $31.50.

Prothena Trading Up 2.6%

Shares of PRTA stock traded up $0.12 on Friday, reaching $4.78. The company's stock had a trading volume of 549,184 shares, compared to its average volume of 691,107. The stock's fifty day simple moving average is $8.70 and its 200-day simple moving average is $12.36. Prothena has a 1 year low of $4.32 and a 1 year high of $25.42. The company has a market capitalization of $257.29 million, a price-to-earnings ratio of -2.08 and a beta of 0.11.

Prothena (NASDAQ:PRTA - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The biotechnology company reported ($1.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.92) by ($0.20). The firm had revenue of $2.83 million for the quarter, compared to analysts' expectations of $8.18 million. Prothena had a negative net margin of 90.50% and a negative return on equity of 22.67%. The company's revenue for the quarter was up 5500.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.34) EPS.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Virtus ETF Advisers LLC increased its stake in shares of Prothena by 19.3% during the fourth quarter. Virtus ETF Advisers LLC now owns 5,148 shares of the biotechnology company's stock worth $71,000 after purchasing an additional 833 shares in the last quarter. GAMMA Investing LLC increased its stake in Prothena by 4,626.0% during the 1st quarter. GAMMA Investing LLC now owns 6,002 shares of the biotechnology company's stock worth $74,000 after buying an additional 5,875 shares in the last quarter. Headlands Technologies LLC increased its stake in Prothena by 196.5% during the 4th quarter. Headlands Technologies LLC now owns 7,330 shares of the biotechnology company's stock worth $102,000 after buying an additional 4,858 shares in the last quarter. Cambridge Investment Research Advisors Inc. purchased a new stake in shares of Prothena during the first quarter worth approximately $126,000. Finally, Teacher Retirement System of Texas purchased a new stake in shares of Prothena during the fourth quarter worth approximately $145,000. Hedge funds and other institutional investors own 97.08% of the company's stock.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.